Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.4907 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC(O)=C24
InChI
InChIKey=OPIKUXLJQFYMSC-UHFFFAOYSA-N
InChI=1S/C24H28N2O3/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21/h5-11,16,25,27H,3-4,12-15H2,1-2H3
ADL5859 (or ADL-5859) is Adolor Corporation developed a novel, oral compound that targets the delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain. ADL-5859 was in the phase II of clinical trial for the treatment of neuropathic pain, acute pain, and pain due to osteoarthritis of the knee and for patients with osteoarthritis. Further development of this drug as potential pain treatments was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
FA554TW3UP
Created by
admin on Mon Mar 31 21:59:37 GMT 2025 , Edited by admin on Mon Mar 31 21:59:37 GMT 2025
|
PRIMARY | |||
|
850305-06-5
Created by
admin on Mon Mar 31 21:59:37 GMT 2025 , Edited by admin on Mon Mar 31 21:59:37 GMT 2025
|
PRIMARY | |||
|
11417954
Created by
admin on Mon Mar 31 21:59:37 GMT 2025 , Edited by admin on Mon Mar 31 21:59:37 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
